• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form F-10POS filed by HEXO Corp.

    6/22/23 5:08:06 PM ET
    $HEXO
    Pharmaceuticals and Biotechnology
    Health Care
    Get the next $HEXO alert in real time by email
    F-10POS 1 brhc20054773_f10pos.htm F-10POS
    As filed with the Securities and Exchange Commission on June 22, 2023

    Registration No. 333-228924
    Registration No. 333-255264

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    POST-EFFECTIVE AMENDMENT NO. 2
    TO
    FORM F-10
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

    HEXO Corp.
    (Exact name of Registrant as specified in its charter)

    Ontario, Canada
    2833
    Not Applicable
    (Province or other Jurisdiction of Incorporation or Organization)
    (Primary Standard Industrial Classification Code Number)
    (I.R.S. Employer Identification Number, if applicable)

    265 Talbot Street West
    Leamington, Ontario, Canada
    N8H 4H3
    (844) 845-7291
    (Address and telephone number of Registrant’s principal executive offices)

    Tilray Brands, Inc.
    655 Madison Avenue, 19th Floor
    New York, New York 10065
    (844) 845-7291
    (Name, address (including zip code) and telephone number (including area code) of agent for service in the United States)

    Copies to:
    Christopher P. Giordano
    Stephen P. Alicanti
    DLA Piper LLP (US)
    1251 Avenue of the Americas
    New York, NY 10020
    (212) 335-4500

    Approximate date of commencement of proposed sale of the securities to the public:
    Not applicable.

    Province of Quebec, Canada
    (Principal jurisdiction regulating this offering)

    It is proposed that this filing shall become effective (check appropriate box):

    A.
    ☒ upon filing with the Commission, pursuant to Rule 467(a) (if in connection with an offering being made contemporaneously in the United States and Canada).
    B.
    ☐  at some future date (check the appropriate box below).
     
    1.  
    ☐
    pursuant to Rule 467(b) on ( ) at ( ) (designate a time not sooner than 7 calendar days after filing).
     
    2.  
    ☐
    pursuant to Rule 467(b) on ( ) at ( ) (designate a time 7 calendar days or sooner after filing) because the securities regulatory authority in the review jurisdiction has issued a receipt or notification of clearance on ( ).
     
    3.  
    ☐
    pursuant to Rule 467(b) as soon as practicable after notification of the Commission by the Registrant or the Canadian securities regulatory authority of the review jurisdiction that a receipt or notification of clearance has been issued with respect hereto.
     
    4.  
    ☐
    after the filing of the next amendment to this Form (if preliminary material is being filed).
     
    If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to the home jurisdiction’s shelf prospectus offering procedures, check the following box. ☐



    EXPLANATORY NOTE
     
    DEREGISTRATION OF SECURITIES AND WITHDRAWAL OF REGISTRATION STATEMENT
     
    HEXO Corp. (the “Registrant”) initially filed the Registration Statement on Form F-10 (File No. 333-228924) with the Securities and Exchange Commission (the “SEC”) on December 20, 2018 (the “2018 Registration Statement”), which became automatically effective upon filing. Pursuant to Rule 429 under the Securities Act of 1933, as amended, this Post-Effective Amendment No. 2 (this “Post-Effective Amendment”) also relates to the Registration Statement on Form F-10 (File No. 333-255264) filed with the SEC on April 15, 2021, which became automatically effective on May 10, 2021 upon the filing of a pre-effective amendment and was further amended by a post-effective amendment which became automatically effective on May 28, 2021 (as so amended, the “2021 Registration Statement” and, together with the 2018 Registration Statement, the “Registration Statements”). The Registration Statements registered for sale an indeterminate number of securities, including common shares, warrants, subscription receipts and units (collectively, the “Securities”), with an aggregate initial offering price of USD$1,554,800,000.
     
    As previously publicly announced, the Registrant is party to an arrangement agreement, dated April 10, 2023, as amended on June 1, 2023, between the Registrant and Tilray Brands, Inc. (“Tilray”), pursuant to which the Registrant and Tilray executed an arrangement (the “Arrangement”) under the Business Corporations Act (Ontario) on June 22, 2023 under the terms of which the Registrant and Tilray consummated transactions resulting in the purchase by Tilray of all of the issued and outstanding common shares of the Registrant.
     
    In connection with the completion of the transactions contemplated by the Arrangement, the Registrant has terminated any and all offerings of its securities pursuant to the Registration Statements. This Post-Effective Amendment is being filed to deregister all of the Securities formerly issuable and registered under the Registration Statements and not otherwise sold by the Registrant as of the date hereof, and to discontinue the effectiveness of the Registration Statements.
     

    SIGNATURES
     
    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-10 and has duly caused this Post-Effective Amendment No. 2 to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Leamington, Ontario, on June 22, 2023.

       
    HEXO CORP.
       
     
    By:
    /s/ Blair MacNeil
       
    Name:
    Blair MacNeil
       
    Title:
    President

    Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 2 to the Registration Statements has been signed by the following persons in the following capacities on June 22, 2023.

    SIGNATURE
    TITLE
       
    /s/ Blair MacNeil
    President and Director
    Blair MacNeil
    (Principal Executive Officer)
       
    /s/ Carl Merton
    Chief Financial Officer and Treasurer and Director
    Carl Merton
    (Principal Financial and Accounting Officer)


    AUTHORIZED REPRESENTATIVE
     
    Pursuant to the requirements of Section 6(a) of the Securities Act of 1933, the undersigned has signed this Post-Effective Amendment No. 2 to the Registration Statements, solely in the capacity of the duly authorized representative of the Registrant in the United States, on June 22, 2023.

       
    TILRAY BRANDS, INC.
         
     
    By:
    /s/ Mitchell Gendel
       
    Name:
    Mitchell Gendel
       
    Title:
    Global General Counsel



    Get the next $HEXO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HEXO

    DatePrice TargetRatingAnalyst
    3/4/2022$1.00 → $1.25Hold → Speculative Buy
    Canaccord Genuity
    3/4/2022Hold → Speculative Buy
    Canaccord Genuity
    3/4/2022$1.20 → $0.90Neutral
    Cantor Fitzgerald
    1/27/2022$1.07 → $0.53Underperform → Hold
    Jefferies
    12/15/2021$2.00 → $0.80Neutral → Underperformer
    CIBC
    12/15/2021Neutral → Sector Underperform
    CIBC
    12/15/2021$2.10 → $1.20Neutral
    Cantor Fitzgerald
    10/29/2021$2.29 → $2.10Neutral
    Cantor Fitzgerald
    More analyst ratings

    $HEXO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HEXO upgraded by Canaccord Genuity with a new price target

      Canaccord Genuity upgraded HEXO from Hold to Speculative Buy and set a new price target of $1.25 from $1.00 previously

      3/4/22 8:45:54 AM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • HEXO upgraded by Canaccord Genuity

      Canaccord Genuity upgraded HEXO from Hold to Speculative Buy

      3/4/22 7:41:12 AM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • Cantor Fitzgerald reiterated coverage on HEXO with a new price target

      Cantor Fitzgerald reiterated coverage of HEXO with a rating of Neutral and set a new price target of $0.90 from $1.20 previously

      3/4/22 6:18:18 AM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care

    $HEXO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by HEXO Corp. (Amendment)

      SC 13G/A - HEXO Corp. (0001690947) (Subject)

      2/8/23 3:28:12 PM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form SC 13G filed by HEXO Corp.

      SC 13G - HEXO Corp. (0001690947) (Subject)

      2/8/22 3:16:31 PM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form SC 13G/A filed by HEXO Corp. (Amendment)

      SC 13G/A - HEXO Corp. (0001690947) (Subject)

      11/16/21 8:34:29 AM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care

    $HEXO
    Financials

    Live finance-specific insights

    See more
    • HEXO to Host Third Quarter 2023 Earnings Conference Call

      This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated May 2, 2022 to its short form base shelf prospectus dated May 7, 2021 and amended and restated on May 25, 2021 HEXO Corp. (TSX:HEXO, NASDAQ:HEXO) ("HEXO" or the "Company"), a leading producer of high-quality cannabis products, announced today that it will hold an audio-only conference call on Thursday, June 15, 2023, at 10 a.m. EDT, to review its financial results for the third fiscal quarter, ended April 30, 2023. The results will be released after market close on Wednesday, June 14, 2023. Following the prepared remarks, there will be a question-and-answer session. Ch

      6/12/23 5:10:00 PM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • Tilray Brands Reports Third Quarter Fiscal Year 2023 Financial Results and Announces Accretive Acquisition of 100% of HEXO Corp.

      Delivered $145.6 Million in Net Revenue and 16th Consecutive Quarter of Positive Adjusted EBITDA Maintained #1 Cannabis Market Share Position in Canada, the Largest Federally Legal Cannabis Market in the World; With HEXO Transaction, Poised to Substantially Increase Canadian Revenue Medical Cannabis Leader in Europe Achieved Key Efficiency Milestones on Accelerated Path to Positive Cash Flow, Company Reiterates Cash Flow Guidance LEAMINGTON, Ontario and NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) --  Tilray Brands, Inc. ("Tilray" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide commun

      4/10/23 4:15:00 PM ET
      $HEXO
      $TLRY
      Pharmaceuticals and Biotechnology
      Health Care
      Medicinal Chemicals and Botanical Products
    • HEXO to Host Second Quarter 2023 Earnings Conference Call

      This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated May 2, 2022 to its short form base shelf prospectus dated May 7, 2021 and amended and restated on May 25, 2021 HEXO Corp. (TSX:HEXO, NASDAQ:HEXO) ("HEXO" or the "Company"), a leading producer of high-quality cannabis products, announced today that it will hold an audio only conference call on March 17, 2023, at 10 a.m. EDT, to review its financial results for the second fiscal quarter, ended January 31, 2023. The results will be released after market close on Thursday, March 16, 2023. Following the prepared remarks, there will be a question-and-answer session. Charlie Bo

      3/14/23 7:00:00 AM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care

    $HEXO
    Leadership Updates

    Live Leadership Updates

    See more
    • HEXO Announces Election of Directors

      HEXO Corp. (TSX:HEXO, NASDAQ:HEXO) ("HEXO"), a leading producer of high-quality cannabis products, today announced that at the annual general meeting of shareholders held on January 31, 2023 (the "Meeting"), each of the eight director nominees was elected as a director of HEXO. Detailed results of the vote are set out below. Nominee Votes For Votes Withheld Total Votes Cast Percentage of Votes For Percentage of Votes Withheld Mark Attanasio 2,063,211 434,874 2,498,058 82.592% 17.408% Vincent Chiara 1,983,425 514,662 2,498,087 79.398% 20.602% Denise Faltischek 2,072,889 425,198 2,498,087 82.979% 17.021% Hélène

      1/31/23 5:30:00 PM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • HEXO Announces Leadership Transition; Company Appoints Charlie Bowman as Chief Executive Officer and Julius Ivancsits as Chief Financial Officer

      Scott Cooper Steps Down; Board of Directors Acknowledge Cooper in Stabilizing the Company Bowman and Ivancsits to Lead HEXO's Continued Transformation and Growth GATINEAU, Quebec, April 29, 2022 (GLOBE NEWSWIRE) -- HEXO Corp ("HEXO" or the "Company") (TSX:HEXO, NASDAQ:HEXO) today announced that Charlie Bowman has been appointed the Company's acting President and Chief Executive Officer, effective today. Mr. Bowman will move into a permanent role upon the successful completion of Health Canada's security clearance process for key personnel, which has been initiated. Concurrently, Scott Cooper is stepping down from his role as HEXO's President and Chief Executive Officer. "I am honoured t

      4/29/22 9:00:00 AM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • HEXO Announces the Appointment of a New Board Member and Acting CFO

      This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated May 11, 2021 to its short form base shelf prospectus dated May 7, 2021 and amended and restated on May 25, 2021. GATINEAU, Quebec, Jan. 05, 2022 (GLOBE NEWSWIRE) -- HEXO Corp ("HEXO", or the "Company") (TSX:HEXO, NASDAQ:HEXO), today announced the appointment of William Todd Montour to the Company's Board of Directors following the resignation of Jason Ewart, effective immediately. "I am pleased to welcome Will to the Board, and I am confident that his experience in cannabis operations and commercialization will be invaluable to the Company as we enter our next stage of

      1/5/22 8:05:00 AM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care

    $HEXO
    SEC Filings

    See more
    • SEC Form 15-12G filed by HEXO Corp.

      15-12G - HEXO Corp. (0001690947) (Filer)

      7/3/23 4:15:19 PM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form 25-NSE filed by HEXO Corp.

      25-NSE - HEXO Corp. (0001690947) (Subject)

      6/22/23 5:20:40 PM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form F-10POS filed by HEXO Corp.

      F-10POS - HEXO Corp. (0001690947) (Filer)

      6/22/23 5:08:06 PM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care

    $HEXO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HEXO Corp. Announces Completion of Acquisition by Way of Arrangement With Tilray Brands, Inc.

      HEXO Corp. (TSX:HEXO, NASDAQ:HEXO) ("HEXO" or the "Company") announced today the closing of the second of two tranches of the non-brokered private placement of Series 1 Preferred Shares (the "Private Placement") previously announced on June 1, 2023 and the subsequent completion of the transactions contemplated by the previously announced statutory plan of arrangement under section 182 of the Business Corporations Act (Ontario) (the "Arrangement") involving the Company and Tilray Brands, Inc. ("Tilray"). "On behalf of HEXO's board and management team, I'd like to extend our deepest thanks to the entire HEXO team for their continued commitment to our business and customers," said Charlie Bow

      6/22/23 5:02:00 PM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • HEXO Corp. Announces Receipt of Final Order for Arrangement With Tilray Brands, Inc.

      HEXO Corp. (TSX:HEXO, NASDAQ:HEXO) ("HEXO" or the "Company") announced today that the Ontario Superior Court of Justice (Commercial List) (the "Court") has granted the final order (the "Final Order") in connection with the previously announced statutory plan of arrangement under section 182 of the Business Corporations Act (Ontario) (the "Arrangement"), pursuant to which Tilray Brands, Inc. ("Tilray") will acquire all of the issued and outstanding common shares (the "Common Shares") and non-voting Series 1 Preferred Shares of the Company. Holders of Common Shares of the Company (the "Common Shareholders") will receive 0.4352 of a share of Tilray common stock (the "Tilray Shares") for each w

      6/19/23 4:06:00 PM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • HEXO Reports Q3'23 Financial Results

      HEXO Corp. (TSX:HEXO, NASDAQ:HEXO) ("HEXO" or the "Company"), a leading producer of high-quality cannabis products, today reported its financial results for the third quarter of the 2023 fiscal year ("Q3'23"). All currency amounts are stated in Canadian dollars unless otherwise noted. "In the third quarter, we entered into a definitive arrangement agreement whereby Tilray will acquire all outstanding shares of HEXO," said Charlie Bowman, President and Chief Executive Officer of HEXO. "We continue to expect the transaction will be completed by June 30, 2023." "HEXO recorded $21.6 million in net revenues in the third quarter, representing an 11% decline from the second quarter," noted Jul

      6/14/23 4:51:00 PM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care